- 前收市價
321.81 - 開市
319.59 - 買盤 283.53 x 100
- 賣出價 311.79 x 100
- 今日波幅
293.80 - 321.12 - 52 週波幅
260.52 - 346.85 - 成交量
6,633,075 - 平均成交量
1,855,434 - 市值 (當日)
160.636十億 - Beta 值 (5 年，每月) 0.60
- 市盈率 (最近 12 個月)
38.21 - 每股盈利 (最近 12 個月)
7.82 - 業績公佈日 2025年2月4日 - 2025年2月10日
- 遠期股息及收益率 9.00 (2.80%)
- 除息日 2024年11月18日
- 1 年預測目標價
335.10
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout. It also markets other products, including Neulasta, MVASI, AMJEVITA/AMGEVITA, TEZSPIRE, Parsabiv, Aimovig, LUMAKRAS/LUMYKRAS, EPOGEN, KANJINTI, TAVNEOS, RAVICTI, UPLIZNA and PROCYSBI. The company serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. The company has collaboration agreements with AstraZeneca plc for the development and commercialization of TEZSPIRE; Novartis Pharma AG to develop and commercialize Aimovig; UCB for the development and commercialization of EVENITY; Kyowa Kirin Co., Ltd. for rocatinlimab development and commercialization; and BeiGene, Ltd. for oncology products expansion and development. Amgen Inc. was incorporated in 1980 and is headquartered in Thousand Oaks, California.
www.amgen.com26,700
全職員工
12月31日
會計年度終止日
Healthcare
界別
Drug Manufacturers - General
行業
最新新聞: AMGN
更多內容
表現總覽: AMGN
截至 12/11/2024 的累計總回報，可能包括股息或其他分派。 基準是
.本年度至今日回報
1 年回報
3 年回報
5 年回報
比較: AMGN
選擇以關鍵表現數據分析類似公司；最多可選擇 4 個股份。
統計資料: AMGN
更多內容價值評估
市值
172.98B
企業價值
224.37B
追蹤市盈率
41.10
預測市盈率
15.60
市盈增長率 (預期 5 年)
2.31
股價營收比 (過去 12 個月)
5.34
股價淨值比 (最近一季)
22.98
企業價值/收入
6.90
企業價值/除利息、稅項、折舊及攤銷前盈利
16.64
財經焦點
盈利能力與損益表
利潤率
13.00%
資產回報率 (過去 12 個月)
4.60%
股本回報率 (過去 12 個月)
55.72%
收益 (過去 12 個月)
32.53十億
可供普通股分配之淨收益 (過去 12 個月)
4.23十億
攤薄每股盈利 (過去 12 個月)
7.82
資產負債表與現金流量
總現金 (最近一季)
9.01十億
總負債/股東權益 (最近一季)
802.42%
槓桿自由現金流 (過去 12 個月)
4.57十億